Gilead Sciences Price Target Raised by Royal Bank Of Canada

Analysts boost price target to $123 for the biopharmaceutical company

Apr. 7, 2026 at 1:57pm

Got story updates? Submit your updates here. ›

An extreme close-up of the inner workings of a high-tech pharmaceutical manufacturing facility, with a focus on the complex gears, pipes, and mechanical components that represent the technological and financial infrastructure supporting Gilead Sciences' drug development efforts.The behind-the-scenes machinery powering Gilead Sciences' pharmaceutical innovations.Foster City Today

Royal Bank Of Canada has raised its price target for Gilead Sciences (NASDAQ:GILD) from $118.00 to $123.00 and maintained a 'sector perform' rating on the stock. The new target price represents a potential downside of 11.26% from the company's current trading price.

Why it matters

Gilead Sciences is a major biopharmaceutical company known for its antiviral therapies, particularly for HIV and viral hepatitis. Analyst price target changes can impact investor sentiment and trading activity around the stock.

The details

In a research note, analysts at Royal Bank Of Canada cited Gilead Sciences' recent financial performance and product pipeline as factors behind the price target increase. The company reported strong Q4 2025 results, with revenue and earnings exceeding analyst expectations.

  • The new price target was issued on April 7, 2026.

The players

Royal Bank Of Canada

A major Canadian multinational financial services company that provides various banking, wealth management, and capital markets products and services.

Gilead Sciences

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, including antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

Gilead Sciences' strong financial performance and pipeline have led to a modest price target increase from Royal Bank Of Canada, reflecting the company's continued importance in the biopharmaceutical industry.